加载中
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
前收盘价
US$0.9032
+US$0.0322 · +3.70%
盘后
US$0.8944
−US$0.0088 · -0.97%
10月12日 19:41 ET
盘中时间采用ET。市场数据可能有所延迟。
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
日内区间
当前US$0.9032
52周区间
当前US$0.9032
盘中时间采用ET。市场数据可能有所延迟。
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
日内区间
当前US$0.9032
52周区间
当前US$0.9032
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 10万 USD | 40万 USD | 22.5万 USD | — | 188.4万 USD |
| 销货成本 | — | — | — | — | 379.1万 USD |
| 毛利 | 10万 USD | 40万 USD | 22.5万 USD | — | −190.7万 USD |
| 研究与开发 | 1964.3万 USD | 831.2万 USD | 518.5万 USD | 1032.7万 USD | 982.7万 USD |
| 销售、一般及管理费用 | 1059.5万 USD | 1069万 USD | 1167.4万 USD | 1845.1万 USD | 1796.3万 USD |
| 营业费用 | 3524.1万 USD | 1900.2万 USD | 1685.9万 USD | 2934.3万 USD | 2779万 USD |
| 利息收入 | 215万 USD | 43.7万 USD | 36.3万 USD | 21.3万 USD | 17.7万 USD |
| 利息支出 | 5.3万 USD | 21.2万 USD | 17.2万 USD | 8.3万 USD | 141.2万 USD |
| 折旧和摊销 | 103万 USD | 112.6万 USD | 125万 USD | 138万 USD | 379.1万 USD |
| 营业利润 | −3514.1万 USD | −1860.2万 USD | −1663.4万 USD | −2934.3万 USD | −2969.7万 USD |
| 净利润 | −3304.4万 USD | −1837.7万 USD | −2490.7万 USD | −6501万 USD | −5039.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 453.59%评级样本有限，仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年11月29日 | 1:20 | — | — |
股票拆分 | 2022年10月10日 | 1:25 | — | — |
股票拆分 | 2018年6月11日 | 1:10 | — | — |
已生效 2023年11月29日
1:20
已生效 2022年10月10日
1:25
已生效 2018年6月11日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
